热门资讯> 正文
Ascendis获得FDA批准用于治疗生长激素缺乏症
2025-07-29 00:09
- The U.S. FDA has approved Ascendis Pharma's (ASND) Skytrofa (lonapegsomatropin) as a once-weekly treatment for adults with growth hormone deficiency (GHD).
- Skytrofa, which acts as a replacement of endogenous growth hormone, was previously approved by the agency in 2021 as a pediatric GHD therapy.
- Approval was based on the results of a phase 3 trial that compared the efficacy of weekly Skytrofa, also known as TransCon hGH, with daily somatropin weekly placebo and in adults with GHD.
More on Ascendis Pharma
- Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript
- Ascendis Pharma reports positive results from hypothyroid trial
- Ascendis rises after FDA priority review for genetic condition treatment
- Seeking Alpha’s Quant Rating on Ascendis Pharma
- Historical earnings data for Ascendis Pharma
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
